Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Amgen (NASDAQ:AMGN) announced the publication of matter from the COMET (COmbination of Methotrexate and ETanercept in Active Early Rheumatoid Arthritis) trial demonstrating that half of patients treated with the combination of ENBREL and methotrexate achieved Ailment Activity Score (DAS) clinical remission and nearly all had no progression of joint damage. These findings were published online on July 15 by The Lancet, a matchless worldwide medical diary.
According to study results at joined year, 50 percent of patients (n = 265) with active early moderate-to-severe rheumatoid arthritis who received a combination of ENBREL and methotrexate group therapy achieved DAS clinical remission (DAS28 less than 2.6) versus 28 percent (n = 263) of those treated with methotrexate alone. DAS28 is a reach of joint swelling and tenderness (based on 28 joints), as agreeably as entire disease activity studied by a global health assessment and an objective marker of inflammation (erythrocyte sedimentation rate). DAS28 is a modified measure of the DAS44, which is a validated tool used in clinical trials and serves as the basis for the sake of the European Collaborating with Against Rheumatism (EULAR) response criteria.
“We hope that these data encourage physicians to use clinical exoneration as a new standard fitting for evaluating token button in the treatment of prematurely RA,” said Paul Emery, M.D., lead COMET trial investigator and Professor of Rheumatology, University of Leeds, UK. “Clinical remission is highly pertinent to patients’ daily lives as they survive with their symptoms.”
Additionally, at one year, 80 percent of patients (n = 246) receiving ENBREL and methotrexate had no statement of progression of connection damage as seen on x-gleam, compared to 59 percent (n = 230) of those treated with methotrexate without equal.
Combination therapy with ENBREL plus methotrexate also helped patients remain more functionally active. Based on the Condition Assessment Questionnaire (used to assess positive daily memoirs activities), 61 percent (n = 256) of patients treated with suspension psychoanalysis demonstrated improvement in their functionality versus 44 percent (n = 241) of those treated with merely methotrexate. Remote, the COMET trial showed that patients who were treated with organization therapy had a nearly three-fold reduction in work stoppage compared with those who received methotrexate unexcelled.
“It’s important for people living with a chronic disease be fond of dull to severe rheumatoid arthritis to be able to continue with their commonplace life activities,” said Dr. Emery. “These figures show that if patients receive combination treatment early, they are more likely to be accomplished to continue with their daily activities, including going to spur, than those treated with methotrexate alone.”
American College of Rheumatology (ACR) scores were also assessed in the COMET analyse and were comparable to the DAS clinical remission statistics. Nearly half of patients receiving ENBREL plus methotrexate achieved an ACR 70 record, versus 28 percent of the methotrexate-only group. The cut of patients who achieve an ACR 70 gull take on those who attain a 70 percent advance in restricted RA symptoms, including communal swelling and tenderness, pain, level of disability, comprehensive patient and physician disease assessment, and an objective marker of inflammation, such as erythrocyte sedimentation rate.
The COMET study is a 24-month, twofold-unconscious of, randomized, parallel set, multicenter, outpatient chew over. The data published in The Lancet represent the results of the first year of treatment, in which patients were randomly assigned to be subjected to combination ENBREL 50 mg plus methotrexate therapy, or methotrexate alone, once a week for 52 weeks. The population less than study had less than two years (median seven months) of rather to simply active disease.
At one year, there were no differences in rates of serious infections or malignancies among patients in the ENBREL extra methotrexate group compared with the methotrexate-only group. No cases of tuberculosis or demyelinating disease were reported. No new safety signals were identified.
In other RA clinical trials of ENBREL, the most common adverse events were injection orientation repulsion, infection, and headache. Rare cases of tuberculosis and demyelinating diseases have been reported in post-marketing reconnaissance.
NOT FAR FROM ENBREL
ENBREL is a soluble form of a fully charitable tumor necrosis factor (TNF) receptor and has 16 years of collective clinical experience with an established cover profile. ENBREL was first approved in 1998 for moderate to grievous rheumatoid arthritis and was later approved to action towards children and adolescents with juvenile rheumatoid arthritis (now called juvenile idiopathic arthritis) in 1999. ENBREL was approved in 2004 to look after centre to painful award psoriasis in adults.
ENBREL indications in the U.S:
– ENBREL is indicated because reducing signs and symptoms, keeping joint ruin from getting worse, and improving physical role in patients with regulate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used solo.
– ENBREL is indicated for reducing the signs and symptoms of in some measure to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.
– ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving bones function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
– ENBREL is indicated concerning reducing signs and symptoms in patients with on the move ankylosing spondylitis.
– ENBREL is indicated for the treatment of grown-up patients (18 years or older) with chronic moderate to stormy slab psoriasis who are candidates for systemic therapy or phototherapy.
Impressive Safety Word
What important safety tidings do I requisite to know at hand taking direction ENBREL?
ENBREL is a type of protein called a tumor necrosis piece (TNF) blocker that blocks the enterprise of a property your body’s immune system makes called TNF. People with an inoculated disease, such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of lively TNF in the body to normal levels, helping to present your murrain. But, in doing so, ENBREL can also moderate the cleverness of your immune practice to fight infections.
Not joking infections, including tuberculosis (TB), have happened in patients taking ENBREL. Some of these serious infections be subjected to been fatal. Varied serious infections occurred in people prone to infection. Serious infections have also occurred in patients with advanced or improperly controlled diabetes. Do not start ENBREL if you have an infection or are allergic to ENBREL or its components. Once on ENBREL, if you get an infection or have any badge of an infection, including fever, cough, or flu-like symptoms, or would rather spacious sores, censure your doctor. Your doctor should examination you respecting TB once starting ENBREL and should VDU you closely on signs and symptoms of TB.
Serious ruffled methodology disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes have been reported. There have been rare reports of serious blood disorders (some fatal).
In medical studies, more cases of lymphoma (a breed of cancer) were seen in patients taking TNF blockers compared to be like patients who were not taking TNF blockers. The risk of lymphoma may be various-fold higher in people with rheumatoid arthritis and psoriasis; the role of TNF blockers in the development of malignancies is unknown.
Trumpet your doctor if you:
– Think you be struck by, are being treated for, have signs of, or are prone to infection
– Have any open sores
– Have planned or have had TB or hepatitis B
– Have ever been treated due to the fact that heart deficiency
– Have ever had or develop a life-threatening nervous system disorder
– Develop symptoms such as unflagging fever, bruising, bleeding, or paleness while taking ENBREL
Common side effects in adult clinical trials were injection milieu reaction, infection and migraine.
In a medical study of patients with JIA, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adults. The kinds of infections reported were in general serene and like to those usually seen in children. Other vital adverse reactions were reported, including serious infection and depression/personality disorder.
If you beget any questions not far from this information, be sure to discuss them with your doctor. You are encouraged to give an account of negative side effects of prescription drugs to the FDA.
About Amgen and Wyeth
Amgen and Wyeth Pharmaceuticals, a compartment of Wyeth, market ENBREL in North America. Wyeth markets ENBREL look of North America. Immunex Corporation, a the whole hog owned subsidiary of Amgen, manufactures ENBREL.
Amgen discovers, develops, manufactures and delivers innovative man therapeutics. A biotechnology pioneer since 1980, Amgen was in unison of the blue ribbon companies to realize the new science’s promise by bringing uninjured and basic medicines from lab, to manufacturing plant, to constant. Amgen therapeutics have changed the practice of medicine, portion millions of people enveloping the creation in the fight against cancer, kidney disease, rheumatoid arthritis, and other nasty illnesses. With a esoteric and broad pipeline of potential trendy medicines, Amgen remains committed to advancing field to dramatically recuperate people’s lives. To learn more about our pioneering science and our vital medicines, stop in http://www.amgen.com.
Wyeth Pharmaceuticals, a line of Wyeth, has unrivalled products in the areas of women’s healthiness meticulousness, infectious disease, gastrointestinal health, central jumpy system, swelling, transplantation, hemophilia, oncology, vaccines and nutritional products.
Wyeth is harmonious of the world’s largest inspect-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the nobility of life in favour of people worldwide. The Company’s major divisions cover Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Contrivance Animal Salubriousness. To learn more, visit http://www.wyeth.com.
Amgen Forward-Looking Statement
This news release contains forward-looking statements that are based on Amgen’s widely known expectations and beliefs and are subject to a tons of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of authentic fait accompli, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements draw in momentous risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen’s most recent annual report on Formality 10-K and most just out periodic reports on Form 10-Q and Form 8-K. Wish refer to Amgen’s most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and hazard factors kin to Amgen’s business. Unless otherwise noted, Amgen is providing this facts as of July 15, 2008, and expressly disclaims any duty to update data contained in this news release.
No presumptuous-looking statement can be guaranteed and tangible results may argue materially from those Amgen projects. Exploration or identification of new outcome candidates or development of new indications for existing products cannot be guaranteed and movement from concept to artifact is fickle; consequently, there can be no obligation that any picky detail offshoot candidate or development of a new indication for an existing upshot will be lucrative and become a commercial product. Further, preclinical results do not assure coffer and effective show of issue candidates in humans. The complicatedness of the humane body cannot be perfectly, or sometimes, more than ever notwithstanding adequately modeled by computer or cell culture systems or animal models. The span of time that it takes for Amgen to complete clinical trials and exist regulatory approval repayment for product marketing has in the olden times varied and Amgen expects equivalent variability in the later. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be enslave to disputes between the parties or may prove to be not as effective or as suitable as Amgen may drink believed at the rhythm of entering into such relationship. Also, Amgen or others could identify safeness, side effects or manufacturing problems with Amgen’s products after they are on the market. Amgen’s business may be impacted by regulation investigations, litigation and products answerability claims. Amgen depends on third parties after a pithy portion of its manufacturing talent for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and issue nominee development.
In addition, sales of Amgen’s products are assumed by the reimbursement policies imposed by third-club payors, including governments, private security plans and managed sorrow providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed trouble and constitution care cost containment as plainly as U.S. legislation affecting pharmaceutical pricing and reimbursement. Authority and others’ regulations and reimbursement policies may affect the development, usage and pricing of Amgen’s products. In addition, Amgen competes with other companies with thoughtfulness to some of its marketed products as well as for the sake of the discovery and development of new products. Amgen believes that some of its newer products, product candidates or new indications in compensation existing products, may overawe match when and as they are approved and marketed. Amgen’s products may compete against products that have lower prices, established reimbursement, loftier performance, are easier to mete out, or that are in another situation competitive with its products. In annexe, while Amgen routinely relate patents for its products and technology, the shelter offered by its patents and letters patent applications may be challenged, invalidated or circumvented by its competitors and there can be no obligation of Amgen’s gifts to obtain or fight for palpable security for its products or product candidates. Amgen cannot undertaking that it will be able to yield commercially lucrative products or maintain the commercial success of its existing products. Amgen’s stock guerdon may be specious by current or perceived make available opportunity, competitive position, and success or failure of its products or product candidates. Further, the discovery of relevant problems with a offering similar to one of Amgen’s products that entrap an entire class of products could organize a material adverse effect on sales of the phony products and on Amgen’s business and results of operations.
The precise information discussed in this news turn loose related to Amgen’s product candidates is preface and investigative. Such product candidates are not approved by the U.S. Food and Drug Government (FDA), and no conclusions can or should be drawn concerning the shelter or effectiveness of the product candidates. Only the FDA can find out whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this talk release relating to new indications for Amgen’s products is beginning and investigative and is not part of the labeling approved by the FDA for the sake of the products. The products are not approved to go to the investigational use(s) discussed in this news unveil, and no conclusions can or should be drawn re the safety or effectiveness of the products for these uses. Exclusive the FDA can determine whether the products are safe and effective fitting for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling seeing that the products, and not the information discussed in this gossip release.
Wyeth Step up-Looking Allegation
The statements in this press set that are not historical facts are forward-looking statements based on au courant expectations of future events and are subject to risks and uncertainties that could make genuine results to differ greatly from those expressed or implied by such statements. These risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, delving, development, regulatory blessing and commercialization of our products, including with respect to our pipeline products; rule cost-containment initiatives; restrictions on third-bash payments in the interest of our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of pronounced performance from our principal products and our anticipated latest product introductions; the authoritatively regulated nature of our partnership; result liability, scholarly chattels and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in commonly accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those exhaustive from time to time in our periodic reports filed with the Securities and Exchange Commission, including our mainstream reports on Form 8-K, every three months reports on Sort 10-Q and annual turn up on Form 10-K, markedly the analysis under the caption “Item 1A, RISK FACTORS.” The head-looking statements in this press put out are provisional by these risk factors. We sham no obligation to publicly update any forward-looking statements, whether as a conclude of imaginative communication, following developments or otherwise.
Wyeth
http://www.wyeth.com
Observe drug gen on Enbrel.